格拉斯哥预后评分在含铂细胞毒化疗后接受免疫治疗的 NSCLC 患者中的意义。

Significance of Glasgow Prognostic Scores in NSCLC Patients Treated With Immunotherapy After Platinum-based Cytotoxic Chemotherapy.

机构信息

Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

出版信息

In Vivo. 2021 Nov-Dec;35(6):3423-3430. doi: 10.21873/invivo.12642.

DOI:10.21873/invivo.12642

PMID:34697178

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8627712/

Abstract

BACKGROUND/AIM: Little is known about the prognostic role of the Glasgow prognostic score (GPS) in non-small cell lung cancer (NSCLC) patients treated with immunotherapy after platinum-based cytotoxic chemotherapy.

PATIENTS AND METHODS

This study used a lung cancer cohort of the Catholic Medical Center of Korea between January 2018 and September 2020.

RESULTS

A total of 78 patients with NSCLC treated with immunotherapy as second or further-line therapy were included. Higher GPS values were significant predictors of shorter immune-related progression-free survival (irPFS) and overall survival (OS). The hazard ratios for irPFS were 0.249 for programmed death-ligand 1 (PD-L1) expression ≥50% and 9.73 for a GPS of 2. Older age, lower PD-L1 expression and higher GPS values were independently associated with shorter OS.

CONCLUSION

Higher GPS values were identified as a poor prognostic factor for OS and irPFS in NSCLC patients who received immunotherapy as second or further-line therapy.

摘要

背景/目的：对于接受铂类细胞毒性化疗后接受免疫治疗的非小细胞肺癌（NSCLC）患者，格拉斯哥预后评分（GPS）的预后作用知之甚少。

患者和方法

本研究使用了韩国天主教医疗中心 2018 年 1 月至 2020 年 9 月的肺癌队列。

结果

共纳入 78 例接受免疫治疗作为二线或进一步治疗的 NSCLC 患者。较高的 GPS 值是免疫相关无进展生存期（irPFS）和总生存期（OS）较短的显著预测因素。程序性死亡配体 1（PD-L1）表达≥50%的 HR 为 0.249，GPS 为 2 的 HR 为 9.73。年龄较大、PD-L1 表达较低和较高的 GPS 值与较短的 OS 独立相关。

结论

较高的 GPS 值被确定为接受二线或进一步免疫治疗的 NSCLC 患者 OS 和 irPFS 的不良预后因素。

相似文献

Significance of Glasgow Prognostic Scores in NSCLC Patients Treated With Immunotherapy After Platinum-based Cytotoxic Chemotherapy.

In Vivo. 2021 Nov-Dec;35(6):3423-3430. doi: 10.21873/invivo.12642.

Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.

JAMA Netw Open. 2019 Jul 3;2(7):e196879. doi: 10.1001/jamanetworkopen.2019.6879.

Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.

Cancer. 2020 Nov 15;126(22):4867-4877. doi: 10.1002/cncr.33142. Epub 2020 Sep 11.

Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials.

Pharmacol Res. 2020 Oct;160:105194. doi: 10.1016/j.phrs.2020.105194. Epub 2020 Sep 13.

Real-World Clinical Impact of Immune Checkpoint Inhibitors in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer After Platinum Chemotherapy.

Clin Lung Cancer. 2019 Jul;20(4):287-296.e4. doi: 10.1016/j.cllc.2019.04.004. Epub 2019 Apr 19.

The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.

Clin Lung Cancer. 2018 Mar;19(2):120-129. doi: 10.1016/j.cllc.2017.10.014. Epub 2017 Oct 28.

Programmed Death Receptor Ligand One Expression May Independently Predict Survival in Patients With Non-Small Cell Lung Carcinoma Brain Metastases Receiving Immunotherapy.

Int J Radiat Oncol Biol Phys. 2020 Sep 1;108(1):258-267. doi: 10.1016/j.ijrobp.2020.04.018. Epub 2020 Apr 23.

Ability of the Glasgow Prognostic Score to predict the tolerability and efficacy of platinum-combination chemotherapy among elderly patients with advanced non-small cell lung cancer.

J Med Invest. 2021;68(3.4):260-264. doi: 10.2152/jmi.68.260.

FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.

Oncologist. 2016 May;21(5):634-42. doi: 10.1634/theoncologist.2015-0507. Epub 2016 Mar 16.

Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer.

Cancer Res Treat. 2019 Jul;51(3):1086-1097. doi: 10.4143/crt.2018.537. Epub 2018 Nov 5.

引用本文的文献

Integrating Clinical and Imaging Markers for Survival Prediction in Advanced NSCLC Treated with EGFR-TKIs.

Cancers (Basel). 2025 Aug 3;17(15):2565. doi: 10.3390/cancers17152565.

Prognostic value of the pretreatment Glasgow prognostic score or modified Glasgow prognostic score in patients with advanced cancer receiving immune checkpoint inhibitors: A systematic review and meta‑analysis.

Oncol Lett. 2025 May 2;30(1):323. doi: 10.3892/ol.2025.15069. eCollection 2025 Jul.

Baseline (modified) Glasgow prognostic score as a predictor of therapeutic response to immune checkpoint inhibitors in solid tumors: A systematic review and meta‑analysis.

Oncol Lett. 2025 Feb 13;29(4):184. doi: 10.3892/ol.2025.14931. eCollection 2025 Apr.

The association of nutritional and inflammatory biomarkers with overall survival in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors.

Thorac Cancer. 2024 Aug;15(23):1764-1771. doi: 10.1111/1759-7714.15401. Epub 2024 Jul 19.

Prognostic Factors in Advanced Non-Small Cell Lung Cancer Patients Treated with Immunotherapy.

Cancers (Basel). 2023 Sep 22;15(19):4684. doi: 10.3390/cancers15194684.

Smoking Status at Time of Diagnosis Affects the Efficacy of Anti-PD-1/L1 Therapy in Patients With Advanced NSCLC.

In Vivo. 2023 Sep-Oct;37(5):2357-2364. doi: 10.21873/invivo.13340.

本文引用的文献

Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors.

Lung Cancer. 2021 Feb;152:27-33. doi: 10.1016/j.lungcan.2020.11.026. Epub 2020 Dec 4.

A nomogram to predict short-term outcome of radiotherapy or chemoradiotherapy based on pre/post-treatment inflammatory biomarkers and their dynamic changes in esophageal squamous cell carcinoma.

Int Immunopharmacol. 2021 Jan;90:107178. doi: 10.1016/j.intimp.2020.107178. Epub 2020 Nov 18.

Pretreatment systemic inflammation response index (SIRI) is an independent predictor of survival in unresectable stage III non-small cell lung cancer treated with chemoradiotherapy: a two-center retrospective study.

Ann Transl Med. 2020 Oct;8(20):1310. doi: 10.21037/atm-20-6484.

Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio associations with heart and body dose and their effects on patient outcomes in locally advanced non-small cell lung cancer treated with definitive radiotherapy.

Transl Lung Cancer Res. 2020 Oct;9(5):1996-2007. doi: 10.21037/tlcr-20-831.

Preoperative prognostic nutritional index predicts risk of recurrence after curative resection for stage IIA colon cancer.

Am J Surg. 2021 Jul;222(1):179-185. doi: 10.1016/j.amjsurg.2020.10.032. Epub 2020 Oct 29.

The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab.

J Thorac Dis. 2020 Apr;12(4):1520-1528. doi: 10.21037/jtd.2020.02.27.

Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy.

Oncologist. 2020 Mar;25(3):e528-e535. doi: 10.1634/theoncologist.2019-0751. Epub 2019 Dec 5.

Can epigenetic and inflammatory biomarkers identify clinically aggressive prostate cancer?

World J Clin Oncol. 2020 Feb 24;11(2):43-52. doi: 10.5306/wjco.v11.i2.43.

IL-6 promotes metastasis of non-small-cell lung cancer by up-regulating TIM-4 via NF-κB.

Cell Prolif. 2020 Mar;53(3):e12776. doi: 10.1111/cpr.12776. Epub 2020 Feb 5.

Prediction of Postoperative Clinical Outcomes in Resected Stage I Non-Small Cell Lung Cancer Focusing on the Preoperative Glasgow Prognostic Score.

Cancers (Basel). 2020 Jan 8;12(1):152. doi: 10.3390/cancers12010152.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

格拉斯哥预后评分在含铂细胞毒化疗后接受免疫治疗的 NSCLC 患者中的意义。

Significance of Glasgow Prognostic Scores in NSCLC Patients Treated With Immunotherapy After Platinum-based Cytotoxic Chemotherapy.

机构信息

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

出版信息

In Vivo. 2021 Nov-Dec;35(6):3423-3430. doi: 10.21873/invivo.12642.

DOI:10.21873/invivo.12642

PMID:34697178

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8627712/

Abstract

PATIENTS AND METHODS

This study used a lung cancer cohort of the Catholic Medical Center of Korea between January 2018 and September 2020.

RESULTS

CONCLUSION

Higher GPS values were identified as a poor prognostic factor for OS and irPFS in NSCLC patients who received immunotherapy as second or further-line therapy.

摘要

背景/目的：对于接受铂类细胞毒性化疗后接受免疫治疗的非小细胞肺癌（NSCLC）患者，格拉斯哥预后评分（GPS）的预后作用知之甚少。

患者和方法

本研究使用了韩国天主教医疗中心 2018 年 1 月至 2020 年 9 月的肺癌队列。

结果

结论

较高的 GPS 值被确定为接受二线或进一步免疫治疗的 NSCLC 患者 OS 和 irPFS 的不良预后因素。

格拉斯哥预后评分在含铂细胞毒化疗后接受免疫治疗的 NSCLC 患者中的意义。

Significance of Glasgow Prognostic Scores in NSCLC Patients Treated With Immunotherapy After Platinum-based Cytotoxic Chemotherapy.

机构信息

出版信息

PATIENTS AND METHODS

RESULTS

CONCLUSION

患者和方法

结果

结论

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

格拉斯哥预后评分在含铂细胞毒化疗后接受免疫治疗的 NSCLC 患者中的意义。

Significance of Glasgow Prognostic Scores in NSCLC Patients Treated With Immunotherapy After Platinum-based Cytotoxic Chemotherapy.

机构信息

出版信息

PATIENTS AND METHODS

RESULTS

CONCLUSION

患者和方法

结果

结论